Figure 4 | Scientific Reports

Figure 4

From: Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients

Figure 4

Comparison of anti-MP65 and anti-β1,6-glucan antibody levels at candidemia diagnosis in survivors and non-survivors among candidemic patients. Panel a: Distribution of individual IgG titers against MP65 or β1,6 glucan in survivors (n = 40) and non-survivors (n = 31). Panel b: Levels of anti-MP65 IgGs in surviving and non-surviving candidemic patients belonging to categories of high mortality risk in our setting (patients aged >65 years, with septic shock or with diabetes mellitus, n survivors vs n non-survivors = 22 vs 25, 15 vs 22 and 4 vs 12, respectively) Logistic regression analysis was used to calculate the Odds ratio for the relationship between survival and anti-MP65 and anti–β1,6-glucan antibody titers.

Back to article page